ENV-501 vs Patritumab Deruxtecan
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: HER3 · full Non-Small Cell Lung Cancer pipeline
ENV-501
Developed by Hummingbird Bioscience
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: July 2027 · NCT06956690 (registry estimate)
No aligned efficacy figure on record for this race.
Patritumab Deruxtecan
Developed by Daiichi Sankyo and partners
NCT05865990 · Phase 2 · completed
The study used a single-arm, open-label design with no placebo or active comparator, so responses cannot be reliably separated from the natural course of disease or other factors. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: August 2029 · NCT07286149 (registry estimate)
Reported efficacy
Efficacy: Local determination of intracranial objective response rate (ORR-IC) in cohort 1 and cohort 2. (From baseline to the date of first documented progression, death from any cause, or treatment discontinuation from any reason, whichever came first, assessed up to 12 months); Efficacy: Overall survival (OS) rate at 3 months in cohort 3. (From baseline up to 3 months): LMD cohort primary endpoint met: 3-month OS rate 65% (Kaplan-Meier estimate 69.6%, 95% CI 52.0-93.2, P < 0.001) (met)
Result source: NCT05865990
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | ENV-501 | Patritumab Deruxtecan |
|---|---|---|
| PFS, median | —Not reported | —Trial running · NCT05338970 |
| OS, median | —Not reported | —Trial running · NCT05338970 |
| ORR | —Not reported | —Trial running · NCT05338970 |
| Duration of response, median | —Not reported | —Trial running · NCT05338970 |
PFS, median
- ENV-501
- —Not reported
- Patritumab Deruxtecan
- —Trial running · NCT05338970
OS, median
- ENV-501
- —Not reported
- Patritumab Deruxtecan
- —Trial running · NCT05338970
ORR
- ENV-501
- —Not reported
- Patritumab Deruxtecan
- —Trial running · NCT05338970
Duration of response, median
- ENV-501
- —Not reported
- Patritumab Deruxtecan
- —Trial running · NCT05338970
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
ENV-501: no structured comparison results are available for Non-Small Cell Lung Cancer.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ENV-501's landscape · Patritumab Deruxtecan's landscape